Get the Stockscreener App
3.54
4.58%
-0.17
After Hours:
3.52
-0.02
-0.56%
Curevac N V Stock (CVAC) Latest News
Deadly Bird Flu Strain Detected In Nevada Man: 4 Stocks To Watch - Benzinga
Individual investors among CureVac N.V.'s (NASDAQ:CVAC) largest stockholders and were hit after last week's 6.1% price drop - Simply Wall St
CureVac (NASDAQ:CVAC) Trading Down 5.8%Here's Why - MarketBeat
Moderna, CureVac, other vaccine stocks jump as new human bird-flu cases reported in U.S., Australia - MSN
CureVac NV (FRA:5CV) Altman Z-Score : 3.43 (As of Feb. 01, 2025) - GuruFocus.com
CureVac NV (FRA:5CV) Momentum Rank : 7 (As of Feb. 01, 2025) - GuruFocus.com
CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting - ACCESS Newswire
CureVac (NASDAQ:CVAC) Shares Sold by Ballentine Partners LLC - Defense World
CureVac Announces Financial Results for the Second Quarter and First Half of 2024 and Provides Business Update - ACCESS Newswire
Brokers Offer Predictions for CureVac FY2025 Earnings - Defense World
22,946 Shares in CureVac (NASDAQ:CVAC) Bought by Barclays PLC - Defense World
CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024 - ACCESS Newswire
FY2025 EPS Estimates for CureVac Raised by Leerink Partnrs - MarketBeat
Companies Like CureVac (NASDAQ:CVAC) Are In A Position To Invest In Growth - Yahoo Finance
CureVac (NASDAQ:CVAC) Stock Price Down 3.7%What's Next? - MarketBeat
CureVac Announces Financial Results for the First Quarter of 2023 and Provides Business Update - ACCESS Newswire
CureVac (NASDAQ:CVAC) Shares Up 4.7%Should You Buy? - MarketBeat
Bird Flu Raising Red Flags Among Health Officials, CDC Urges Faster Testing - Benzinga
Jane Street Group LLC Has $235,000 Stock Position in CureVac (NASDAQ:CVAC) - Defense World
Geode Capital Management LLC Lowers Position in CureVac (NASDAQ:CVAC) - Defense World
CureVac NV (FRA:5CV) 50-Day SMA : €2.91 (As of Jan. 11, 2025) - GuruFocus.com
CVAC (CureVac NV) 14-Day RSI : 68.17 (As of Jan. 10, 2025) - GuruFocus.com
CureVac (NASDAQ:CVAC) Trading 5.7% HigherHere's What Happened - MarketBeat
Why CureVac (CVAC) Shares Are Volatile - Benzinga
CureVac: Latest GBM Data Bodes Well For Next Program Check Point (NASDAQ:CVAC) - Seeking Alpha
Why CureVac (CVAC) Stock Is Moving - Benzinga
CureVac (NASDAQ:CVAC) Shares Gap DownHere's What Happened - MarketBeat
CureVac (NASDAQ:CVAC) Sees Unusually-High Trading VolumeWhat's Next? - MarketBeat
CureVac (NASDAQ:CVAC) Shares Gap UpHere's Why - MarketBeat
Why CureVac (CVAC) Stock Is Rising - Benzinga
Vaccine stocks gain amid uptick in flu, COVID-19, RSV (CVAC:NASDAQ) - Seeking Alpha
Subdued Growth No Barrier To CureVac N.V. (NASDAQ:CVAC) With Shares Advancing 25% - Simply Wall St
Short Interest in CureVac (NASDAQ:CVAC) Declines By 6.4% - MarketBeat
CureVac (NASDAQ:CVAC) Trading Up 3.6% – Still a Buy? - Defense World
CureVac (NASDAQ:CVAC) Stock Quotes, Forecast and News Summary - Benzinga
CureVac (NASDAQ:CVAC) Stock Price Up 3.6%Here's What Happened - MarketBeat
Discover 3 US Penny Stocks With Market Caps Over $200M - Simply Wall St
CureVac (NASDAQ:CVAC) Trading Up 4.7%What's Next? - MarketBeat
CureVac (NASDAQ:CVAC) Shares Down 5.5%What's Next? - MarketBeat
CureVac's SWOT analysis: mRNA pioneer's stock faces oncology pipeline hurdles - Investing.com
2 Small-Cap Stocks Set to Shine in a Bull Market - Benzinga
CUREVAC : Licensing deal boosts bank account - Marketscreener.com
Point72 Asset Management L.P. Sells 1,642,723 Shares of CureVac (NASDAQ:CVAC) - MarketBeat
CUREVAC : Positive one-off overshadows pipeline dryness - Marketscreener.com
CureVac NV (XTER:5CV) 50-Day SMA : €2.62 (As of Dec. 05, 2024) - GuruFocus.com
CureVac NV (STU:5CV) 5-Day RSI : 64.31 (As of Dec. 05, 2024) - GuruFocus.com
CureVac's SWOT analysis: mRNA pioneer's stock faces pivotal phase in oncology push - Investing.com
CureVac NV (LTS:0A9E) EBITDA per Share : $0.84 (TTM As of Sep. 2024) - GuruFocus.com
CureVac NV (LTS:0A9E) Profitability Rank : 3 (As of Sep. 2024) - GuruFocus.com
CureVac NV (LTS:0A9E) 3-Year FCF Growth Rate : 0.00% (As of Sep. 2024) - GuruFocus.com
CureVac NV (HAM:5CV) Cyclically Adjusted FCF per Share : €0.00 (As of Sep. 2024) - GuruFocus.com
CureVac NV (WBO:CVAC) Enterprise Value : €94.9 Mil (As of Dec. 01, 2024) - GuruFocus.com
CureVac NV (HAM:5CV) Altman Z-Score : 2.46 (As of Dec. 01, 2024) - GuruFocus.com
CureVac NV (STU:5CV) 3-Year FCF Growth Rate : 0.00% (As of Sep. 2024) - GuruFocus.com
CureVac NV (STU:5CV) Cyclically Adjusted Revenue per Share : €0.00 (As of Sep. 2024) - GuruFocus.com
CVAC (CureVac NV) 9-Day RSI : 62.66 (As of Nov. 30, 2024) - GuruFocus.com
CVACCureVac N.V. Ordinary Shares Latest Stock News & Market Updates - StockTitan
2.27%
5.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):